Roche Partners with Oryzon Genomics and Spero Therapeutics
By Heather Cartwright
Pharma Deals Review: Vol 2014 Issue 5 (Table of Contents)
Published: 21 May-2014
DOI: 10.3833/pdr.v2014.i5.2029 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
As part of a global collaboration for the development of epigenetics-based therapeutics, Roche has licensed global rights to Oryzon Genomics’ lead drug candidate ORY-1001, an inhibitor of the epigenetic modulator lysine specific demethylase-1 (LSD1; KDM1A) that is in Phase I/IIa development for acute myeloid leukaemia...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS